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Abstract
There is an increase in obesity among the population of industrialized countries, and dietary
supplementation with Conjugated Linoleic Acid (CLA) has been reported to lower body fat mass.
However, weight loss is generally associated with negative effects on bone mass, but CLA is
reported to have beneficial effects on bone. Furthermore, another factor that is well established to
have a beneficial effect on bone is exercise (EX). However, a combination therapy of CLA and EX
on bone health has not been studied. In this paper, we report the beneficial effects of CLA and EX
on bone, in four different groups of Balb-C young, male mice. There were 4 groups in our study:
1. Safflower oil (SFO) sedentary (SED); 2. SFO EX; 3. CLA SED; 4. CLA EX. Two months old mice,
under their respective treatment regimens were followed for 14 weeks. Mice were scanned in vivo
using a DEXA scanner before and after treatment. At the end of the treatment period, the animals
were sacrificed, the left tibia was removed and scanned using peripheral quantitative computerized
tomography (pQCT). The results showed that although CLA decreased gain in body weight by 35%,
it however increased bone mass by both reducing bone resorption and increasing bone formation.
EX also decreased gain in body weight by 21% and increased bone mass; but a combination of CLA
and EX, however, did not show any further increase in bone mass. In conclusion, CLA increases
bone mass in both cancellous and cortical bones, and the effects of CLA on bone is not further
improved by EX in pure cortical bone of young male mice.
Background
Obesity is a major health disorder in the US. About 30.5%
of the adult population in the US is obese [1]. In the last
decade alone the percent of obese people has doubled
according to the National Health and Nutrition Examina-
tion survey [1]. Body Mass Index (BMI) is the tool cur-
rently used to measure excess body weight and BMI of 30
and above represents obesity. The influence of body
weight on bone mass has been extensively studied [2-6].
Increase in body weight increases bone mass and reduc-
tion in body weight decreases bone mineral density
(BMD) [2,4-6]. Since obesity is a growing problem, many
people are turning towards agents that will reduce body
fat mass. Recently, conjugated linoleic acid (CLA) has
been reported to have significant effect on lowering body
fat mass [7]. CLA is a group of fatty acids that has a mix-
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ture of positional and geometric isomers of linoleic acid
with conjugated double bonds, which may be of cis and
trans configuration at positions 9 and 11 or 10 and 12
[8,9]. Several reports have brought to light the beneficial
effects of dietary CLA supplementation in experimental
animals and humans [9-12]. CLA not only reduces body
fat, but also reduces inflammation, has anti carcinogenic
properties, and enhances bone mineralization [13-15].
Several in vitro and in vivo studies have also shown that
CLA has positive influence on bone [12,16,17].
Increase in body weight increases bone mass but aging is
associated with bone loss in both men and women [18].
Bone loss causes thinning of bones thereby increasing the
risk of fractures [19]. In the last decade, more evidence has
suggested that males also lose almost the same amount of
bone as women [20]. The major difference between bone
loss in women and men is that bone loss in women is
severe during and after menopause, while bone loss in
men is very gradual. Every individual loses 0.5–1% of
bone every year, for the rest of their life, after attaining
peak bone mass around their third decade of life [21].
One of every four men, above the age of 50, is susceptible
to osteoporosis related fracture. Elderly men, when they
have fractures are more disabled. Although, several thera-
pies are available for the treatment of osteoporosis, the
risk of side-effects and/or lack of increasing bone anabolic
agents have increased the need for alternate therapies.
Dietary supplementation of beneficial compounds is
encouraged in order to reduce the risk of side-effects.
Since CLA is reported to reduce both body fat as well as
bone loss, it was our interest to study the effects of CLA on
bone mass.
It is very well known that bone formation and resorption
is also influenced by exercise (EX) [22,23]. Exercise exerts
strain on bone, which stimulates bone formation and
decreases bone resorption. According to the 'Mechanostat
theory [24] bone is maintained by a feedback mechanism
such that mechanical strains do not exceed a minimum
effective strain. There are several reports indicating that
exercise increases bone formation [25-28].
In this paper, we investigated whether a significant loss of
body weight and particularly, combined effects of CLA
and exercise on loss of body weight will have any adverse
or beneficial effects on bone mass in young male Balb/C
using Dual Energy X-ray Absorptiometry (DEXA) and
Peripheral Quantitative Computerized Tomography
(pQCT) densitometry. The results show that both CLA
and exercise do not cause any adverse effects but appear to
protect against bone loss during weight loss caused by
CLA and exercise.
Results
Body weights
Mice that were fed CLA had significantly lower gain in
body weight during the treatment period. Figure 1 shows
the change in percent body weight in mice fed the differ-
ent diets. CLA SED treated mice showed a 35% (P < 0.01)
decrease in body weight gain when compared to that of
SFO SED treated mice. As expected mice from both EX
groups also had lower weight gain (21%).
DEXA
Effects of CLA
CLA significantly increased the BMD by 15% (p < 0.05),
12% (p < 0.05), 8% (p < 0.05), 25% (p < 0.05) and 26%
(p < 0.05) in the DFM, FD, TD, L3 and L5 respectively,
when compared to that of SFO SED mice (Table 2).
Effects of EX
EX significantly increased the BMD by 13% (p < 0.05) in
the FD of SFO EX treated mice when compared to that of
SFO SED treated mice. In DFM and lumbar vertebrae also
had higher BMD but this increase was not statistically sig-
nificant (Table 2).
Combined effects of CLA and EX
The BMD values at the different bone sites studied were
found to be lower than that of the CLA SED treated mice.
This decrease was not statistically significant except in the
PTM were a decrease of 7% (p < 0.05) was observed when
compared to that of CLA SED treated mice (Table 2).
Percent change in body weights after the different treatment  regimens Figure 1
Percent change in body weights after the different treatment 
regimens. * p < 0.01 vs SFO SED.   SFO SED = Saf-
flower Oil (SFO) Sedentary (SED);   SFO EX = 
SFO and Exercise (EX); CLA SED = Conjugated 
linoleic acid (CLA) SED; and   CLA EX = CLA and 
EX.
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When compared to SFO EX treated mice there was signif-
icant increase in BMD only in the PTM (10%, p < 0.05)
and TD (8%, p < 0.05). In all other regions studied, the
BMD increased, but this increase was not statistically sig-
nificant (Table 2).
pQCT densitometry
PTM
Effects of CLA
CLA increased Cn. B. Ar. (24%, p < 0.05), Cn. BMD (46%,
p < 0.05), Ct. BMC (24%, p < 0.05), Ct. BMD (17%, p <
0.05), Peri. PM (18%, p < 0.05) and Endo PM (21%, p <
0.05) when compared to those of SFO SED treated mice
(Table 3).
Effects of EX
Although EX did not bring about any significant changes
in the different parameters studied, SFO EX treated mice
showed higher Cn. BMD and Ct. BMD values (Table 3).
Combined effects of CLA and EX
Slight decrease was observed in all the different parame-
ters studied in the CLA EX treated mice when compared to
those of the CLA SED treated mice. These decreases were
not statistically significant except in the Endo PM where
34% (p < 0.05) decrease was observed. (Table 3). Ct. BMD
increased by 8% (p < 0.05) in CLA EX treated mice when
compared to that of SFO EX treated mice.
TF junction
Effects of CLA
CLA increased Ct. BMC, Ct. BMD, Ct. Th, Peri PM and
Endo PM significantly by 29% (p < 0.05), 17% (p < 0.05),
4% (p < 0.05), 25% (p < 0.05) and 19% (p < 0.05) when
compared to those of SFO SED treated mice. The Ct. B. Ar
also increased but this increase was not statistically signif-
icant (Table 4).
Effects of EX
EX also increased all the cortical parameters studied in the
SFO EX treated mice when compared to those of the SFO
SED treated mice, but these increases were not statistically
significant (Table 4).
Combined effects of CLA and EX
CLA EX decreased the Ct. B. Ar, Ct. BMC, Ct. BMD, Ct. Th
and Peri PM by 11% (p < 0.05), 19% (p < 0.05), 9% (p <
0.05), 8% (p < 0.05) and 12% (p < 0.05) respectively,
when compared to those of the CLA SED treated mice
(Table 4).
However, when compared to SFO EX treated mice, CLA
EX treatment increased all the cortical parameters but this
increase was not statistically significant (Table 4).
Discussion
In this study, we observed that there was significant loss of
overall body weight and body fat mass in CLA treated
mice. The detailed results are published elsewhere [7]. In
spite of significant decrease in the gain of body weight in
CLA fed mice, BMD in the lumbar vertebrae and PTM
increased significantly. In the PTM, where both cancellous
and cortical bones are present, CLA increased bone area
and BMD in the cancellous bone suggesting that CLA has
beneficial effects on cancellous bone. CLA also increased
bone mineralization and bone density in the cortical bone
surrounding the cancellous bone in the PTM, showing
that overall CLA has a positive effect on bone. In pure cor-
tical bone (TF), CLA increased bone mass by increasing
the periosteal perimeter. This increase in the periosteal
surface suggests that CLA, to some extent, influences bone
formation as well. Recently, the effects of CLA on bone
have been investigated in a few in vitro as well as in vivo
studies. In vitro studies using MC3T3-E1 osteoblast like
cells showed that CLA increased levels of osteocalcin,
alkaline phosphatase activity and calcium absorption
[29]. Calcium absorption is enhanced in the presence of
polyunsaturated fatty acids (PUFA) [15]. In vivo studies
Table 2: Effects of CLA and EX on BMD (g/cm2) from different bone sites analyzed using DEXA densitometry.
Groups/Bone sites SFO SED SFO EX CLA SED CLA EX
Distal Femoral Metaphysis 0.3355 ± 0.0200a 0.3368 ± 0.0010b 0.3654 ± 0.0001 0.3654 ± 0.0001
Proximal tibial Metaphysis 0.2582 ± 0.0080b 0.2846 ± 0.0060a 0.3053 ± 0.0050 0.2846 ± 0.0060a
Femoral Diaphysis 0.3341 ± 0.0100a,b,c 0.3730 ± 0.0008 0.4059 ± 0.0100 0.3767 ± 0.0009
Tibial Diaphysis 0.1994 ± 0.0008a 0.1944 ± 0.0006a,b 0.2107 ± 0.0003 0.2107 ± 0.0003
Lumbar Vertebra (L3) 0.1956 ± 0.0010a 0.2107 ± 0.0010 0.2449 ± 0.0100 0.2244 ± 0.0008
Lumbar Vertebra (L4) 0.2289 ± 0.0006 0.2572 ± 0.0200 0.2515 ± 0.0010 0.2515 ± 0.0010
Lumbar Vertebra (L5) 0.2076 ± 0.0009a,b 0.2618 ± 0.0006 0.2696 ± 0.0150 0.2696 ± 0.0150
a = p < 0.05 vs CLA SED, b = p < 0.05 vs CLA EX, c = p < 0.05 vs SFO EX. SFO SED = Safflower Oil (SFO) Sedentary (SED), SFO EX = SFO and 
Exercise (EX), CLA SED = Conjugated linoleic acid (CLA) SED, CLA EX = CLA and EX.Lipids in Health and Disease 2006, 5:7 http://www.lipidworld.com/content/5/1/7
Page 4 of 9
(page number not for citation purposes)
using young chicken, mice and pigs have shown that in
the presence of CLA there is generally increased bone
mass. However, in young rats, CLA decreased bone forma-
tion rates [30,31], but when CLA was given along with n-
6 PUFA, bone formation rates increased [32]. In humans,
a study that tested the effects of CLA supplementation on
the biochemical markers of bone metabolism [33] has
reported that in adult men CLA supplementation did not
affect markers of bone metabolism. A recent study on the
effects of CLA on postmenopausal women has concluded
that dietary intake of CLA may benefit BMD [34].
The mechanism by which CLA exerts its effect on bone is
still not very clear, although a few pathways are reported
recently (Fig 2). In vitro studies conducted in our lab
showed that CLA (1 μM) significantly inhibited osteoclas-
togenesis (unpublished data). CLA, in the presence of
PUFA, modulated the action and expression of COX-2
enzyme, thereby altering prostaglandin-dependent bone
resorption [35,36]. CLA also alters leptin concentration
due to its action on adipocytes; leptin expression was
found to be modulated both in in vitro cell cultures as well
as in in vivo animal studies [37-40]. Indeed, CLA may exert
its influence on bone mass through down regulation of
leptin [41,42]. Leptin is reported to decrease the produc-
tion of RANK (Receptor Activated Nuclear Factor) ligand
[43], which regulates osteoclast differentiation and activa-
tion, thereby influencing bone resorption [44]. There is
evidence that leptin also stimulates the formation of oste-
oblasts [42]. Studies have reported that IL-1 and IL-6
induce bone resorption by stimulating the recruitment
and formation of osteoclasts; thereby, releasing calcium
from bone [45,46]. Dietary CLA reduces both pro-inflam-
matory IL-1 [47] and IL-6 production [48] Reduced levels
of leptin and IL-6 were observed in serum of mice from
the present study, and the results are published elsewhere
[7]. The reduction of leptin suggests that CLA may not use
the leptin pathway to reduce bone resorption, but the cir-
culating leptin may be sufficient to stimulate osteoblasts
and in turn increase bone formation on the periosteal sur-
face. Decrease in IL-6 suggests that CLA may use the IL-6
and RANK-L pathways to reduce bone resorption. We,
therefore, believe that CLA may have bone anabolic prop-
erties as well as bone anti-resorption properties similar to
n-3 fatty acids which was found to protect bone loss in
mice prone to develop autoimmune disease [49].
In the present study, EX alone showed a trend towards
increasing bone density in PTM and TF junction. Such
effects of EX on bone has been reported in several studies.
In aged female Sprague Dawley rats, treadmill exercise
increased BMD in the tibial metaphysis and L5 vertebrae.
Table 4: Effects of CLA and EX on the Cortical Bone Parameters of the Tibia Fibular Junction Analyzed by pQCT densitometry.
Groups/Bone Parameters SFO SED SFO EX CLA SED CLA EX
Cortical Bone Area (mm2) 2.779 ± 0.350 2.857 ± 0.120 3.347 ± 0.110 2.995 ± 0.060a
Cortical BMC (mg/mm) 3.303 ± 0.400a 3.672 ± 0.200 4.248 ± 0.070 3.811 ± 0.070a
Cortical BMD (g/mm3) 3647.0 ± 171.3a 3897.0 ± 112.4 4281.0 ± 84.7 3915.0 ± 106.6a
Cortical Thickness (mm) 0.873 ± 0.057a 0.957 ± 0.030 1.044 ± 0.020 0.961 ± 0.020a
Periosteal Perimeter (mm) 11.36 ± 0.89a 12.07 ± 0.43 14.24 ± 0.37 12.58 ± 0.26a
Endocortical Perimeter (mm) 5.746 ± 0.430a 6.809 ± 0.310 6.819 ± 0.148 6.543 ± 0.180
a = p < 0.05 vs CLA SED. SFO SED = Safflower Oil (SFO) Sedentary (SED), SFO EX = SFO and Exercise (EX), CLA SED = Conjugated linoleic acid 
(CLA) SED, CLA EX = CLA and EX.
Table 3: Effects of CLA and EX on the Cancellous and Cortical Bone parameters of the Proximal Tibial Metaphysis Analyzed using 
pQCT densitometry.
Groups/Bone Parameters SFO SED SFO EX CLA SED CLA EX
Cancellous Bone Area (mm2) 4.127 ± 0.200a 4.020 ± 0.400 5.110 ± 0.300 3.890 ± 0.400
Cancellous BMC (mg/mm) 6.893 ± 0.039 6.668 ± 0.058 7.951 ± 0.071 6.663 ± 0.055
Cancellous BMD (g/mm3) 494.6 ± 20.4a 539.9 ± 29.4 721.8 ± 96.1 553.3 ± 39.4
Cortical Bone Area (mm2) 3.749 ± 0.170 3.778 ± 0.270 4.469 ± 0.200 4.055 ± 0.267
Cortical BMC (mg/mm) 3.424 ± 0.180a 3.499 ± 0.240 4.260 ± 0.190 3.972 ± 0.260
Cortical BMD (g/mm3) 2726.0 ± 80.5a,b 2813.0 ± 64.5a,b 3181.0 ± 93.4 3025.0 ± 50.0
Cortical Thickness (mm) 0.759 ± 0.040 0.712 ± 0.040 0.808 ± 0.055 0.799 ± 0.040
Periosteal Perimeter (mm) 18.20 ± 0.70a 17.96 ± 1.10 21.44 ± 0.74 16.60 ± 2.10
Endocortical Perimeter (mm) 13.62 ± 0.49a 13.42 ± 1.05 16.44 ± 1.00 12.28 ± 1.40a
a = p < 0.05 vs CLA SED, b = p < 0.05 vs CLA EX. SFO SED = Safflower Oil (SFO) Sedentary (SED), SFO EX = SFO and Exercise (EX), CLA SED = 
Conjugated linoleic acid (CLA) SED, CLA EX = CLA and EX.Lipids in Health and Disease 2006, 5:7 http://www.lipidworld.com/content/5/1/7
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In these regions, trabecular separation decreased, and
trabecular volume and number increased in exercised rats.
This increase in BMD in cancellous bone can be attributed
to increased bone formation and reduced bone resorption
[28]. In the present study also we found that EX increased
bone formation and decreased bone resorption. In male
rats, it has been reported that EX increased pure cortical
bone area by increasing bone formation [50] similar to
the present study, whereas in the TF junction, BMD and
bone thickness increased in the exercised mice, mainly, by
increasing the periosteal perimeter. EX, in general, brings
about site specific responses on bone [23,25]. BMD is
increased more in cancellous bone than in pure cortical
bone as has been reported earlier in middle-aged Fisher
344 rats [25,26].
In combination, CLA and EX had beneficial effects on
lumbar vertebrae and femoral diaphysis. The combina-
tion treatment did not show any changes in cancellous
bone of the PTM, except that it significantly reduced the
endocortical perimeter, suggesting that in combination
CLA and EX not only inhibited endosteal bone resorption
but also increased endocortical bone formation. In pure
cortical bone, however, effects of CLA and EX are moder-
ate; there was a significant decrease in all the cortical
parameters studied with respect to CLA SED treated mice,
but still higher than the SFO EX treated group. So, CLA
with EX has a positive effect on pure cortical bone, but for
some reason it is not as beneficial as CLA alone. There
maybe several explanations for this. EX by itself, as men-
tioned earlier, is reported to have site-specific effects on
Schematic Representation of the Possible Pathways Involved in the Action of CLA on Bone Mass Figure 2
Schematic Representation of the Possible Pathways Involved in the Action of CLA on Bone Mass. a = decrease bone resorp-
tion; b = increase bone formation.
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bone and is known to have more effect on cancellous
bone than on cortical bone [25,26], similar to what we
observed in this study. It is also possible that EX is able to
modulate the effects of CLA selectively on cortical bone.
Another possibility is that the type and duration of EX
used in this study is insufficient to bring about more
changes to the cortical bone. Whatever the case may be,
the encouraging part is that CLA and EX together is still
beneficial to pure cortical bone.
This is the first report on the combined favorable effects of
CLA and EX on bone mass in young male mice. Based on
our results we have shown that CLA alone is capable of
increasing both cancellous and cortical bone mass;
although, it effectively reduces body weight in this animal
model. It can therefore be suggested that CLA can be used
as an efficient supplement for weight management with-
out having any adverse effects on bone. The question
whether CLA and EX in combination is more beneficial to
bone remains to be clarified by undertaking further stud-
ies in young and old mice. Although, in the different bone
sites studied, CLA and EX has a positive effect on bone,
they do not seem to fully compliment each other. In fact,
EX seems to be lowering the effects of CLA on pure cortical
bone. The interaction of CLA and EX at the molecular
level is not known. Further studies are required in this
regard to throw light on how EX modulates the effects of
CLA on bone. However, we conclude that in young male
mice, although, CLA reduces body weight, it actually pro-
tects both cancellous and cortical bone mass and has no
adverse effects on bone due to loss of body weight. EX
does not seem to compliment, any further, the effects of
CLA.
Methods
1. Animals and experimental diets
Six-week-old male Balb/c mice were obtained from Har-
lan, Indianapolis, Indiana Weight matched mice were
housed in laboratory animal care facility in cages (5 mice/
cage) and fed standard lab chow diet. At 8 weeks of age,
animals were divided into four groups: Group 1. AIN-93M
diet with safflower oil (SFO) (0.5%), sedentary (SFO
SED) (n = 6); Group 2. AIN-93M diet with safflower oil
(0.5%), Exercise (SFO EX) (n = 6); Group 3. AIN-93M diet
with CLA (0.5%), sedentary (CLA SED) (n = 6); Group 4.
AIN-93M diet with CLA (0.5%), exercise (CLA EX) (n = 5).
Each diet contained 20% corn oil (CO) as high fat diet.
Groups 3 and 4 received 0.5% CLA (Clarinol TM Powder,
Lipid Nutrition, Channahon, Illinois) (c9t11 and t10c12
isomers in equal proportions together). The composition
of AIN-93M diet is modified form of AIN-93 diet and the
details are provided in table 1. Fresh diet was prepared
weekly, stored in aliquots at -20°C and provided daily ad
libitum.
Animals were maintained on a 12 hr light/12 hr dark cycle
in an ambient temperature of 22–25°C and 45% humid-
ity. Body weight was monitored weekly and food con-
sumption based on residual food was also monitored
everyday. Mice were given the respective diets for 14 weeks
and at the end of which they were sacrificed. The left tibia
was dissected out and stored in 70% ethanol until it was
scanned using pQCT. Animals were handled according to
NIH guidelines provided under "The guide for the care
and use of laboratory animals" and the Institutional Ani-
mal Care and Use Committee of the University of Texas
Health Science Center at San Antonio. The body weight
data has been reported in another publication [7].
2. Exercise protocol
Exercise was performed on a rodent treadmill (Quinton
Instruments,Seattle) with the following protocol as
described by Fernandes et al [51]. After training for several
days on a treadmill containing 10 running compartments,
each mouse thereafter ran for 40 to 50 minutes, 5 days/
week at 0.6 miles/hour and at 10° angle to provide resist-
ance for running. The treadmill consists of rubber belts,
which are driven at a controlled speed. Each mouse was
trained to recognize two signals: breaking an electric beam
(creates noise) and a mild, continuous airflow. The seden-
tary mice were placed on the stationery rodent treadmill,
twice a week, for the same period of time as the exercised
groups.
3. Measurement of bone mineral density (BMD)
BMD was measured by DEXA using a Lunar Piximus
mouse bone densitometer (GE) and data was analyzed
with PIXImus software [52-54]. Before scanning was per-
formed, mice were anesthetized with intra-muscular injec-
tion of mouse cocktail containing-Ketamine (3 cc), S.A.
Rompun (2 cc) and NaCl (5 cc). During the measure-
ments, the mice were lying in a prone position with pos-
terior legs maintained in external rotation with tape. The
Table 1: Composition of semi-purified AIN-93M diet.
Ingredient, g/Kg SFO CLA
Casein 248 248
Salt mix 64 64
Vitamin mix 17 17
Cellulose 55 55
Cerelose 405.5 403.74
Choline bitartrate 2.5 2.5
dl-methionine 3 3
Clarinol powder* 0 6.76
SFO 5 0
Corn oil 200 200
Total 1000 1000
*contains 74% CLA.
SFO = Safflower Oil.
CLA = Conjugated linoleic acidLipids in Health and Disease 2006, 5:7 http://www.lipidworld.com/content/5/1/7
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hip, knee and ankle articulations were in 90° flexion.
BMD was obtained for the entire body except the head.
BMD was then measured manually at the left distal femo-
ral metaphysis (DFM), the proximal tibial metaphysis
(PTM), the tibia fibular junction (TF) and the lumbar ver-
tebra (L3). Baseline scans were first taken before the
administration of the diets and scanning was performed
in live mice at the end of 14 weeks.
4. Peripheral quantitative computerized tomography 
densitometry (pQCT)
The cortical bone at the tibia fibula junction (TF) and the
cancellous and cortical bones at the proximal tibial meta-
physis (PTM) were analyzed by pQCT densitometry, using
a XCT research M system (Norland Stratec, Birkenfeld,
Germany) as described previously [25,26]. In the TF junc-
tion, pure cortical bone was scanned and the following
parameters determined: cortical bone area (Ct. B. Ar), cor-
tical bone mineral content (Ct. BMC), cortical bone min-
eral density (Ct. BMD), cortical thickness (Ct. Th),
periosteal perimeter (Peri. PM) and endocortical perime-
ter (Endo. PM). In the PTM, both cancellous bone and
cortical bone surrounding the cancellous bone were ana-
lyzed, 1 mm distal to the knee joint, and the following
parameters determined: cancellous bone area (Cn. B. Ar),
cancellous bone mineral content (Cn. BMC), cancellous
bone mineral density (Cn. BMD), Ct. B. Ar, Ct. BMC, Ct.
BMD, Ct. Th, Peri. PM and Endo. PM.
5. Statistical analysis
Results are expressed as Mean ± SE. Data were normalized
to body weight and analyzed with one-way ANOVA and
unpaired t-test using GraphPad Prism 4 (GraphPad Soft-
ware Inc, San Diego, CA, USA). p < 0.05 was considered to
be significant. Newman-Keuls multiple comparison test
was used to analyze the differences between groups for
significance.
Abbreviations
CLA Conjugated linoleic acid
EX Exercise
SED Sedentary
CO Corn oil
SFO Safflower oil
pQCT peripheral quantitative computerized tomography
US United States
BMI Body mass index
BMC Bone mineral content
BMD Bone mineral density
DEXA Dual Energy x-ray absorptiometry
DFM Distal Femoral metaphysis
FD Femoral Diaphysis
PTM Proximal tibial diaphysis
TD Tibial Diaphysis
TF Tibia fibular junction
L5 Fifth lumbar vertebra
Cn B Ar Cancellous bone area
Cn BMC Cancellous bone mineral content
Cn BMD Cancellous bone mineral density
Ct B Ar Cortical bone area
Ct BMC Cortical bone mineral content
Ct BMD Cortical bone mineral density
Ct Th Cortical thickness
Peri PM Periosteal perimeter
Endo PM Endocortical perimeter
PUFA Polyunsaturated fatty acid
RANK Receptor Activated Nuclear Factor
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